Candel Therapeutics (NASDAQ:CADL – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.
A number of other research analysts also recently weighed in on CADL. Wall Street Zen downgraded shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Bank of America raised Candel Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $12.00 to $18.00 in a report on Monday, September 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Thursday, October 15th. Citigroup cut their price objective on Candel Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a report on Monday. Finally, Stifel Nicolaus cut their price objective on Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Friday, November 13th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.29.
Get Our Latest Stock Analysis on CADL
Candel Therapeutics Stock Down 7.1%
CADL stock opened at $5.40 on Monday. The stock has a market capitalization of $423.63 million, a P/E ratio of -3.65 and a beta of -0.27. The company has a debt-to-equity ratio of 0.37, a current ratio of 7.57 and a quick ratio of 7.57. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $14.00. The business has a fifty day moving average price of $9.47 and a 200-day moving average price of $8.39.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. Equities analysts forecast that Candel Therapeutics will post -1.22 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Candel Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Candel Therapeutics during the 2nd quarter valued at approximately $51,181,000. Portolan Capital Management LLC grew its holdings in shares of Candel Therapeutics by 1.4% in the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock valued at $36,943,000 after purchasing an additional 48,163 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Candel Therapeutics by 4.1% in the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock worth $3,316,000 after purchasing an additional 12,385 shares during the last quarter. Bank of America Corp DE bought a new stake in Candel Therapeutics in the second quarter worth $2,873,000. Finally, Wellington Management Group LLP bought a new stake in Candel Therapeutics in the second quarter worth $2,119,000. Institutional investors own 13.93% of the company’s stock.
Candel Therapeutics News Summary
These are some of the CADL news items that stood out recently:
- Positive Sentiment: HC Wainwright maintained a “Buy” rating and an $18 price target, and raised its FY2026 earnings estimate to a smaller expected loss. That optimism is tempered by reductions to its longer-term forecasts.
- Neutral Sentiment: Analyst estimates continue to project losses in the near term. Brookline Capital Markets’ quarterly forecasts mostly indicate ongoing losses through 2027, rather than a near-term return to profitability.
- Negative Sentiment: HC Wainwright cut its projected earnings for 2027–2030, including reducing its FY2029 and FY2030 estimates. These lower out-year expectations weaken the longer-term earnings outlook despite the firm’s Buy rating.
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
